Maria Rosaria Pavone-Cossut
Overview
Explore the profile of Maria Rosaria Pavone-Cossut including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
75
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cafaro A, Schietroma I, Sernicola L, Belli R, Campagna M, Mancini F, et al.
Int J Mol Sci
. 2024 Feb;
25(3).
PMID: 38338977
Each time the virus starts a new round of expression/replication, even under effective antiretroviral therapy (ART), the transactivator of viral transcription Tat is one of the first HIV-1 protein to...
2.
Tripiciano A, Picconi O, Moretti S, Sgadari C, Cafaro A, Francavilla V, et al.
EBioMedicine
. 2021 Apr;
66:103306.
PMID: 33839064
Background: Low-level HIV viremia originating from virus reactivation in HIV reservoirs is often present in cART treated individuals and represents a persisting source of immune stimulation associated with sub-optimal recovery...
3.
Ferrantelli F, Maggiorella M, Schiavoni I, Sernicola L, Olivieri E, Farcomeni S, et al.
Vaccine
. 2011 Feb;
29(16):2918-32.
PMID: 21338681
HIV native Tat and V2 loop-deleted Env (EnvΔV2) proteins already proved safe and immunogenic in phase I clinical testing as single vaccine components. Further, a phase II vaccine trial with...
4.
Borsetti A, Baroncelli S, Maggiorella M, Moretti S, Fanales-Belasio E, Sernicola L, et al.
Viral Immunol
. 2009 Mar;
22(2):117-24.
PMID: 19326998
We previously reported that cynomolgus monkeys vaccinated with the human immunodeficiency virus (HIV)-1 Tat protein controlled infection after challenge with the simian human immunodeficiency virus (SHIV) 89.6P(cy243) for up to...
5.
Maggiorella M, Sernicola L, Crostarosa F, Belli R, Pavone-Cossut M, Macchia I, et al.
J Med Primatol
. 2007 Aug;
36(4-5):180-94.
PMID: 17669207
Background: Vaccine combining structural and regulatory proteins is an emerging approach to develop an HIV/AIDS vaccine and therefore, the immunogenicity and efficacy of two regimens of immunization combining structural (Gag/Pol,...
6.
Bona R, Macchia I, Baroncelli S, Negri D, Leone P, Pavone-Cossut M, et al.
Virus Res
. 2007 Mar;
126(1-2):86-95.
PMID: 17336416
Several studies have shown the importance of evaluating Recent Thymic Emigrants (RTEs) by quantification of T cell receptor-rearrangement excision circles (TRECs), as a measure of de novo T cell generation...
7.
Goletti D, Macchia I, Leone P, Pace M, Sernicola L, Pavone-Cossut M, et al.
Med Sci Monit
. 2006 Sep;
12(10):BR330-40.
PMID: 17006396
Background: The Delta-nef live attenuated virus vaccine approach offered in the SIV-macaque model the opportunity to identify humoral and cell-mediated immune responses associated with protection against viral infections. In addition,...
8.
Maggiorella M, Baroncelli S, Michelini Z, Fanales-Belasio E, Moretti S, Sernicola L, et al.
Vaccine
. 2004 Aug;
22(25-26):3258-69.
PMID: 15308348
Vaccination with a biologically active Tat protein or tat DNA contained infection with the highly pathogenic SHIV89.6P virus, preventing CD4 T-cell decline and disease onset. Here we show that protection...
9.
Fanales-Belasio E, Cafaro A, Cara A, Negri D, Fiorelli V, Butto S, et al.
DNA Cell Biol
. 2002 Oct;
21(9):599-610.
PMID: 12396602
Vaccination against human immunodeficiency virus (HIV)-1 infection requires candidate antigen(s) (Ag) capable of inducing an effective, broad, and long-lasting immune response against HIV-1 despite mutation events leading to differences in...